针对人类膀胱癌的自体抗体。
Autologous antibodies to human bladder cancer.
作者信息
Grossman H B, Wedemeyer G, Stein J
机构信息
Department of Surgery, University of Michigan Medical Center, Ann Arbor 48109.
出版信息
Cancer Immunol Immunother. 1988;26(3):269-72. doi: 10.1007/BF00199940.
The autologous serologic reactivity of 13 patients with bladder cancer was evaluated using cell lines derived from each individual's own tumor as targets. Protein A and immune adherence assays were employed to determine antibody binding to the tumor targets at varying passage numbers. Autologous reactivity was found in 6 of the 13 cell lines tested. However, the titer was usually low regardless of the passage number. Seven autologous serum/cell line combinations were tested using both low and high passage cells as targets. In six of these combinations, the degree of antibody binding was similar with both low and high passage target cells. The incidence of autologous reactivity in the 12 patients with urothelial tumors was 50%.
使用源自每位患者自身肿瘤的细胞系作为靶标，对13例膀胱癌患者的自体血清反应性进行了评估。采用蛋白A和免疫黏附试验来确定在不同传代次数时抗体与肿瘤靶标的结合情况。在所检测的13个细胞系中，有6个发现了自体反应性。然而，无论传代次数如何，滴度通常都很低。使用低传代和高传代细胞作为靶标，对7种自体血清/细胞系组合进行了检测。在这些组合中的6种中，低传代和高传代靶细胞的抗体结合程度相似。12例尿路上皮肿瘤患者的自体反应性发生率为50%。
Zotero 插件